Skip to main content
Sign In

Search

Note: This page will take a moment to download because of the quantity of trials.

Subscribe

Learn about the latest research trials with our daily email.
 

Feedback

Did you have problems using this page? Please fill out our Feedback Form

Clinical Trials

Volunteer to Be Part of a Research Study

Page through all School of Medicine clinical and research trials below. There are two categories:

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please
submit your Web ad here.
  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 136.
COMIRB Approved Advertisement TitleStudy GoalsEligibility CriteriaDate PostedCategory
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 136.
Do you have Parkinson's Disease?
To explore the effects of different doses of endurance exercise in people with PD.​
Persons 40-80 who have been diagnosed with Parkinson's Disease and are not yet taking medication or plant to start medication within the next 6 months. You must be willing to begin the exercise program immediately or after a delay of 6 months and willing to do aerobic exercise on a treadmill.
4/29/2016 
Do you have Atopic Dermatitis (Eczema)?
To study eczema
Males and Females between 3 and 80 who have atopic dermatitis or males and females between 8 months and 80 who have a history of, or an active case of eczema hereticum (wide-spread herpes skin infection along with atopic dermatitis.
4/29/2016 
Better Control of Type 2 Diabetes May Decrease Your Risk for Cardiovascular Disease.
To look at the use of an extended release formula of Exenatide compared to a placebo to maintain normal glucose levels. Ultimately to see better control of diabetes and a decrease in cardiovascular disease events.​
Person 18+ with Type 2 Diabetes and take no more than 2 diabetes medications with stale doses for the last 3 months. Must not have a planned or anticipated revascularization procedure, but may have a history of cardiovascular disease and must see your primary care physician at least twice a year.
4/29/2016 
Type 2 Diabetes and Exercise Research Study
To research the effects of an investigational drug on exercise capacity and blood vessel function​.​
Person 30-60 with Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure. Must not have smoked for at least one year and have a BMI between 25-39.9.
4/29/2016 
Are you a Non-smoking Adult between the ages of 45 and 85?
We are interested in learning more about smoking related lung disease, and need healthy non-smoking participants.
45-85 years old Non-Hispanic White or African American No smoking history No evidence of lung disease
4/29/2016 
Volunteers needed to Participate in a Research Study about Rheumatoid Arthritis
The purpose of this study is to learn more about how rheumatoid arthritis develops by studying people who do not have rheumatoid arthritis. Your participation in this study will help us determine if certain genetic and environmental factors affect the chances of developing RA-related autoantibodies in absence of rheumatoid arthritis.
You may be eligible to participate in the study if: -You are at least 40 years old -You do NOT have Rheumatoid Arthritis (RA)
4/29/2016 
Restoring Insulin Secretion (RISE)
The Children’s Hospital Colorado Clinical Translational Research Center and the National Institutes of Health are conducting a study. This study is aimed at testing whether early treatment is beneficial to kids with early type 2 diabetes and kids at high risk of diabetes.
10-19 years of age, Pubertal, Overweight, Fasting glucose: >90 mg/dl; Impaired glucose tolerance: >140 mg/dl; Pre-diabetes or diagnosed with diabetes for less than 6 months; Metformin
4/29/2016 
Do You Smoke?
To figure out how these lung substances work in people who drink too much alcohol, who usually smoke, compared to those who do not drink heavily, but who smoke.
Smoking and nonsmoking males
4/29/2016 
Parents or Legal Guardians of Children with Disabilities
Assistive Technology Partners, University of Colorado, Anschutz Medical Campus, is performing a study investigating the impact Socially Assistive Robotics has on motor, communication and cognitive skills of children with disabilities.
Children between the ages of 18 months to 5 years of age Have Significant motor and communication disabilities/delays NOT been diagnosed with blindness or deafness They are without a seizure disorder or with a well-controlled seizure disorder They have been on stable medication regime for the past 12 weeks, if they are currently taking medication.
4/29/2016 
The Influence of Couples' Conversation on the Heart
The purpose of the study is to examine the influence that conversations between married couples have on the functioning of the heart.
Married Christian couples who: • Have been married for at least 1 yr. • Both believe in prayer. • Are not currently taking heart medications. • Do not have heart problems. • Are not pregnant.
4/29/2016 
Help Us Learn About Schizophrenia!
Help us learn more about a new drug that may improve thinking and concentration in people with schizophrenia.
We are looking for: Male and female adults who smoke 18-50 years old No previous or current mental illness No drug use Willing to use nicotine patch during study hospital visit If female, willing to use birth control during the study
4/29/2016 
Research Trial Evaluating a New Drug in Psoriasis: Now Enrolling
The study will evaluate an investigational drug compared to a currently approved psoriasis medication. Your participation will provide valuable information to researchers seeking new and improved therapies. You will be given either Humira, placebo, or the investigational drug for up to 28 weeks, after which you may be switched over to the active drug depending on your response.
You may be eligible to participate if 18 years of age or older and have been diagnosed with moderate to severe plaque-type psoriasis for at least 6 months.
4/29/2016 
DO YOU LIKE TO EAT? HEALTHY MEN needed to participate in a research study
Research whether age affects how fat tissue responds to 1 week of overfeeding
Men who are age 25-40 yr or 55-75 yr overweight or mildly obese sedentary to moderately active non-smokers
4/29/2016--Select a Category--
Exercise for Healthy Aging
To determine whether a high versus a moderate intensity of cardiovascular + strength training has a greater improvement on health and quality of life.
Eligibility: Men aged 50-68, no major health problems that would interfere with the ability to exercise; if diabetic, must be well-controlled on oral medications (no insulin); body mass index between 20 and 40; no current/chronic infections.
4/29/2016--Select a Category--
Do you have high blood pressure?
Study to help predict if blood pressure medications will work for you.
You may be eligible if you are an adult aged 30-80 with a diagnosis of uncontrolled essential hypertension. You must not have a history of end stage liver or renal disease, cannot be pregnant, and cannot be allergic to metoprolol.
4/29/2016Heart and Blood Diseases
Give Us a Hand
To better understand Multiple Sclerosis in children and teens.
Between the ages of 3-20 AND have Multiple Sclerosis diagnosed before 18 OR Do not have MS
4/28/2016 
Are you an African American with asthma?
 We are studying why some African American people have trouble with their asthma despite taking asthma medications.
 Children age 5-17 and non-smoking Adults age18 and older who have asthma symptoms despite asthma treatment • African American ancestry (have at least one    African American grandparent)
4/28/2016 
Peanut and Tree-Nut Allergy Research Study
The purpose of this study is to determine how the body's immune system interacts with nuts and other foods to cause allergic reaction.
6-75 years of age. Have a diagnosis of peanut and/or tree-nut allergy made by either skin test or blood tests. Have no known peanut and/or tree-nut allergy.
4/28/2016 
Do you have human growth hormone (hGH) deficiency?
Primary: To demonstrate a clinical superiority of MOD-4023 over placebo in terms of decrease in Fat Mass (FM) in adult subjects with Growth Hormone Deficiency Secondary a. To determine the efficacy of MOD-4023 over placebo in other body composition variables (such as lean body mass and waist-to-hip ratio) b. To evaluate the safety and tolerability of MOD-4023 over placebo in adult subjects with GHD c. To determine the IGF-I and IGFBP-3 serum levels
Adult men and women aged 23 to 70 years of age diagnosed with either adult or childhood onset growth hormone deficiency (GHD).
4/28/2016 
Are you a parent of a child with a developmental disability and willing to contribute to a research project to increase awareness and understanding?
The purpose of this study is to gain knowledge on the topic of everyday stressors that affect the lives of children with developmental disabilities, as well as their parents/caregivers
Are you a parent of a child with a developmental disability and willing to contribute to a research project to increase awareness and understanding?
4/28/2016 
Healthy Female Adults Needed!!!
For brain imaging research study on how the brain works with we taste sweets. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 22 to 29 who are right-handed, free of medication with no serious medical conditions, permanent metal implants or braces/retainers, and are at a healthy body weight.
4/28/2016 
Do you have an egg allergy?
To see if taking Baked Egg Therapy vs. Oral Immunotherapy may help egg-allergic children tolerate eggs.
males and females 3 to 16 years old, with documented egg allergy, ability to make regular visits to National Jewish Health for up to 2 years.
4/28/2016 
Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
Pitavastatin is a statin that along with diet is used for the treatment of high cholesterol. It also lowers triglyceride levels in the blood. The main purpose of this clinical trial is to see if pitavastatin can prevent heart disease and heart disease related deaths in people with HIV infection who are taking HIV medications.
This study lasts about 6 years (21 visits) and you may be eligible if: • You have HIV and are between the ages of 40 and 75. • You have been on antiretroviral therapy (ART) for at least 6 months. • You have a CD4+ cell count > 100. • You have no history of cardiovascular disease (history of heart attack or stroke, etc.). • You are not currently using a statin drug.
4/28/2016 
We are looking for Healthy Men and Women to participate in a research study to determine how Exercise Impacts Fat Metabolism During Sleep
The University of Colorado Anschutz Medical Campus is recruiting healthy men and women to participate in a research study investigating how exercise performed during the day impacts hormones and metabolism during sleep.  Adults spend about one-third of their lives sleeping yet little is known about metabolism during this period or how day time exercise influences sleeping metabolism.  Learning more about sleeping metabolism will improve our understanding of how the body regulates body weight.
This research study is looking for healthy men and women aged 20 to 35 years, who have a BMI < 30, exercise less than 3 days per week, and have a regular sleep schedule.
4/28/2016Nutritional and Metabolic Diseases
Are you Interested in Being in a Weight Loss Research Study?
Volunteers needed for a research study to determine the best time to begin exercise within a lifestyle weight loss program.
• Be a man or woman between 18 and 55 years old • Be generally healthy without diabetes or heart disease • Be a non-smoker • Not currently exercising regularly • Have a BMI between 28 and 40 kg/m2 In order to enroll all participants must meet specific criteria. The criteria listed above is only a partial list of all the requirements to participate in this research study. Only a clinical research staff member can determine eligibility.
4/28/2016Nutritional and Metabolic Diseases
Paid Volunteers Needed for high blood pressure study
Looking for participants in clinical studies. Tests conducted to evaluate Blood Pressure devices per FDA requirements.
Subjects must be 3 years of age and have an arm circumference between 12-55cm.  Looking for healthy Adults, and Kids, non-medicated High Blood Pressure, and individuals with large arms/biceps.  Studies conducted year round on an on-going basis. Payment made on a per study basis, typical $50-100/study.
 
4/28/2016Heart and Blood Diseases
Are You a Healthy Individual Looking to Help With Research
This is a research study to learn more about the risk factors, features, and treatment or prevention efforts for bleeding disorders.
Aged 1 to 17 Healthy
4/28/2016--Select a Category--
Are you interested in participating in a research study to help us learn more about where the fat tissue in your body originates? MYTH Study
This research study plans to learn more about where the fat cells in your body come from.  Understanding the origin of fat cells is important because it may help to determine the health of fat cells and why fat that is stored in some places of your body is more "unhealthy" than other fat.
We are enrolling men and women who are: Age 21-40 y or 55-85 y; BMI 22-35 kg/m2; Weight stable (not actively gaining or trying to lose weight); Non-active to moderately active (exercise ≤ 3 days/wk lasting < 30 min); Not taking any hormonal therapy (testosterone, estrogen/progesterone replacement, or hormonal contraceptives); Not diagnosed with type 2 diabetes or taking glucose or lipid lowering medication; Not pregnant or planning to become pregnant in the next month
4/28/2016Nutritional and Metabolic Diseases
Healthy Volunteers Needed for a Drug-Drug Interaction Research Study
The study will look at the levels of dolutegravir (a HIV medication) and simeprevir (a Hepatitis C medication) in the blood when given alone and in combination.
We are looking for men and women who are: -HIV and Hepatitis C negative -Age 18-60 -Do not have chronic health conditions requiring medications, including but not limited to, high blood pressure, diabetes, eczema, or psoriasis -Not taking any medications except aspirin, Tylenol, ibuprofen, or oral contraceptives
4/28/2016--Select a Category--
Research study on the effects of an investigational drug on weight and neuronal response
This research study plans to examine the effects of an investigational new drug on neuronal, physiological, and behavioral mechanisms of obesity in the general population.
To be eligible for the study, participants must have a BMI greater than 27 kg/m2, be 21-65 years old, be a non-smoker, have no known cardiovascular disease, have no significant endocrine/metabolic disease, must not be pregnant or trying to conceive, and must be able to complete an MRI scan.
4/28/2016Behaviors and Mental Disorders

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
123
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 3, items 1 to 30 of 71.
Protocol TitlePI NameInstitution Number
Data pager
<
123
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 3, items 1 to 30 of 71.
INSULIN RESISTANCE AND ADENOMAS OF THE COLORECTUM (IRASC)
Sedjo, Rebecca L.01-039
INTERAGENCY REGISTRY OF MECHANICALLY ASSISTED CIRCULATORY SUPPORT (INTERMACS)
Cleveland, Joseph C06-0312
A PHASE 1 TRIAL OF PF-03084014 IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCY AND T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA. Sponsor Protocol No. A8641014-1004; WIRB Protocol No. 20090536
Messersmith, Wells Alton09-0166
Evaluation of Thriving After Cancer Treatment is Complete (TACTIC) Clinic
Overholser, Linda Sue09-0597
A Phase I, Multicenter, Open-Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients with Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK). Sponsor Protocol CLDK378X2101. WIRB Protocol No. 20110186
Camidge, David Ross11-0221
The effects of protective stabilization on two-year follow-up patterns of pediatric dental patients
Chin, Katherine Leong11-0523
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. Sponsor Protocol DMO4993g. WIRB Protocol No.20111410
Weekes, Colin Dexter11-1211
A Phase 1 and Pharmacologic Study of MM-151 in Patients with Refractory Advanced Tumors. Sponsor Protocol MM-151-01-01-01/ WIRB Protocol No. 20120026
Lieu, Christopher H11-1825
A Phase 1 Pharmacokinetic and Safety Study of Pacilitaxel Injection Concentrate for Nano-Dispersion (PICN) Alone and in Combination with Carboplatin in Subjects with Advanced Solid Malignancies. Sponsor Protocol No. CLR 10 23. WIRB Protocol No. 20120626
Jimeno, Antonio12-0489
A Phase 1 Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Crizotinib in Advanced Cancer Patients. Sponsor Protocol No. A8081012. WIRB Protocol No. 20120634
O'Bryant, Cindy L12-0515
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered with Bevacizumab and/or Chemotherapy in Patients with Advanced Solid Tumors. Sponsor Protocol GP28328. WIRB Protocol No. 20121229
Eckhardt, Sue G12-0927
Heart Failure Symptom Clusters and Heart Failure Self-care: an exploratory descriptive study
McDermott, Carrie Martha12-1608
A Phase I, multi-center, non-randomized, open label, parallel-group study evaluating the pharmacokinetics and safety of regorafenib (BAY 73-4506) in cancer subjects with severe renal impairment compared to a control group. Sponsor Protocol No. BAY 73-4506 / 16653. WIRB Protocol No. 20130998
O'Bryant, Cindy L13-1882
A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects with Advanced or Metastatic Solid Tumors. Sponsor Protocol No. RX-5902-P1-01. WIRB Protocol No. 20131320
Eckhardt, Sue G13-2176
A PHASE 1B OPEN-LABEL THREE-ARM MULTI-CENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF PF-05212384 (PI3K/mTOR INHIBITOR) IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS. Sponsor Protocol No. B2151002. WIRB Protocol No. 20131499
Leong, Stephen13-2359
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer. Sponsor Protocol No. 18R5-003. WIRB Protocol No. 20131595
Messersmith, Wells Alton13-2391
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects with Advanced Malignancies. Sponsor Protocol No. ORAX-01-13-US. WIRB Protocol No. 20131698
Jimeno, Antonio13-2451
A MULTI-CENTER,OPEN LABEL, FIRST IN HUMAN, PHASE I DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6839921, AN MDM2 ANTAGONIST FOLLOWING INTRAVENOUS ADMINISTRATION IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA (AML). Sponsor Protocol No. NP28903. WIRB Protocol No. 20140542
Gore, Lia13-2649
A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Sponsor Protocol No. VRXP-A202. WIRB Protocol No. 20131627
Jimeno, Antonio13-2911
Quantifying Surgeon Physical Discomfort Among Otolaryngologists
Terella, Adam13-3169
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation Sponsor Protocol No. AG120-C-002 WIRB Protocol No. 20140544
Gore, Lia14-0012
A Phase Ib dose escalation/randomized phase II multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Sponsor Protocol No. CBYL719X2104. WIRB Protocol No.20140692
Jimeno, Antonio14-0034
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects with Advanced Solid Tumors. Sponsor Protocol No. PT-112-101. WIRB Protocol No. 20140867
Camidge, David Ross14-0151
A MULTICENTER PHASE 1A/1B ASCENDING DOSE STUDY OF DCC-2701 TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS IN PATIENTS WITH ADVANCED SOLID TUMORS Sponsor Protocol No. DCC-2701-01-001 WIRB Protocol No. 20142004
Leong, Stephen14-0244
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects with and without Type 2 Diabetes. Sponsor Protocol No. G-04. WIRB Protocol No. 20150046
Hill, James O14-0383
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination with Topotecan (Hycamtin®) in Patients with Solid Tumors. Sponsor Protocol No. ME-344-002, WIRB Protocol No. 20140982
Diamond, Jennifer R14-0413
A Phase I, Dose-escalation Study of the Safety, Pharmacokinetics and Efficacy of Weekly Intravenous Briciclib in Patients with Advanced Solid Tumors Sponsor Protocol No. 08-02 WIRB Protocol No. 20141094
Jimeno, Antonio14-0565
A PHASE 1, DOSE ESCALATION STUDY OF PF-06664178 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS Sponsor Protocol No. B7401001 WIRB Protocol No. 20141074
Messersmith, Wells Alton14-0581
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction with Midazolam, and Safety and Tolerability in Patients with Advanced Malignancies Sponsor Protocol No. OPZ009 WIRB Protocol No. 20141700
Gore, Lia14-0589
A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy. Sponsor Protocol No. ALDOXORUBICIN-PE-STS-01. WIRB Protocol No. 20141245
Elias, Anthony David14-1004


Contact Us

Building 500 - 13001 E. 17th Place, Campus Box C290, Aurora, CO 80045

Learn more